Bradley McGregor, MD, explains patient considerations that come into play now that there are several promising treatment options, such as dual immunotherapy combos and immunotherapy/TKI combos, in the frontline setting for the treatment of patients with renal cell carcinoma. McGregor is clinical director, Lank Center for Genitourinary Oncology, senior physician, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute.
Grant awarded to aid development of allogeneic CAR T treatment for RCC
April 29th 2024“This clinical study has the potential to demonstrate the value of Chimeric Antigen Receptor (CAR) T cell therapy in solid cancers such as kidney cancer with a high unmet medical need,” said Abla Creasey, PhD.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.